Protective Immunity Project 02 (PIP-02)
Influenza (Flu) vaccine is recommended for kidney transplant patients who are at least 6 months post-transplant. The influenza vaccine stimulates the immune system to builds protective antibodies against the flu virus.
Previous research has shown that adult kidney transplant patients are not able to form as much of these protective antibodies as compared to healthy volunteers. Research has also suggested that different immunosuppressive medicines may have different effects on antibody formation. In this study, we hope to evaluate these differences in more detail.
In recent years, increasingly effective, but also increasingly complex, immunosuppressive regimens have been developed, however, there has been little detailed systematic study of the immune changes that occur in response to vaccination with these newer immunosuppressive regimens.Current policies on vaccination of transplant recipients are generic and continue to be based on old concepts rather than on any new understanding of the effects of these newer therapies on the immune system.
We hope to improve our understanding of the effects of the immunosuppressive regimens in use today (calcineurin-inhibitor, or CNI, and sirolimus-based regimens) on immune response to flu vaccine. Such knowledge will be critical to helping clinicians develop strategies for getting desirable immune responses while not causing rejection.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||A Prospective Comparison of the Magnitude and Character of the Immune Response to Influenza Vaccine in Immunosuppressed Renal Transplant Patients and Healthy Age-matched Volunteers|
- To determine the effect of immunosuppressive regimens on the magnitude and character of the adaptive immune response to flu vaccine [ Time Frame: 7, 14, 28 and 90 days post vaccination ] [ Designated as safety issue: No ]
- To determine the effects of chronic immunosuppressive therapies on innate immunity during response to flu vaccine [ Time Frame: 7, 14, 28 and 90 days post vaccination ] [ Designated as safety issue: No ]
- To define the transcriptional and protein signatures of the response to flu vaccination in patients on conventional immunosuppressive regimens compared to healthy volunteers [ Time Frame: 7, 14, 28 and 90 days post vaccination ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||November 2006|
|Study Completion Date:||October 2011|
|Primary Completion Date:||February 2010 (Final data collection date for primary outcome measure)|
Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing sirolimus
Age, gender- and race-matched individuals, not on immunosuppressive medications
Please refer to this study by its ClinicalTrials.gov identifier: NCT00833651
|United States, Georgia|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Christian P. Larsen, MD, DPhil||Emory University|
|Principal Investigator:||Kenneth E Kokko, MD, PhD||Emory University|